Dr. O'Connor Discusses Acalabrutinib in MCL

Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma (MCL).

The label for acalabrutinib is for patients with relapsed or refractory MCL, and does not signify whether it should be used after failing initial therapy with ibrutinib (Imbruvica), says O’Connor. This means that sequencing remains unclear.

O’Connor says that the bigger question is whether treatment with one BTK inhibitor takes away the benefit from another.